{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-020751","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.001368+00:00","generated_at":"2026-06-19T14:00:40.895915+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics Q1 loss widens to $18.7M; PDUFA goal date August 29, 2023","bullets":["Net loss $18.7M ($0.08/share) vs $14.5M ($0.08) in Q1 fiscal 2022.","Cash and equivalents $52.3M; raised $24M equity and $30M convertible note in Dec 2022.","FDA PDUFA goal date for ONS-5010 (wet AMD) set for August 29, 2023.","Pre-launch commercial activities underway; partnership with AmerisourceBergen.","EMA MAA accepted for ONS-5010; decision expected early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-020751","json":"https://secwatch.observer/filing/0001104659-23-020751.json","markdown":"https://secwatch.observer/filing/0001104659-23-020751.md","text":"https://secwatch.observer/filing/0001104659-23-020751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/0001104659-23-020751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/tm236701-1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T14:00:40.895915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dbdbd724e74cca7e3b7006a109f4819a07c8284","claim":"Outlook Therapeutics, Inc. reported fiscal first quarter ended December 31, 2022 results: net income $18.7 million, or $0.08 per basic and diluted share, EPS $0.08 per basic and diluted share.","evidence_excerpt":"On February 14, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/0001104659-23-020751-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal first quarter ended December 31, 2022"},{"label":"Net income","value":"$18.7 million, or $0.08 per basic and diluted share"},{"label":"EPS","value":"$0.08 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}